ADC Linkers and Linker Attachment

Antibody–Drug Conjugates (ADCs) are sophisticated therapeutic agents consisting of monoclonal antibodies covalently bound to cytotoxic drugs through chemical linkers. The success of ADCs hinges on the use of innovative linking technologies, which ensure efficient attachment of the payload to the antibody, provide stability during circulation, and enable precise release of the payload at the target site. We are deeply committed to advancing ADC development through the creation of cutting-edge linking strategies and the synthesis of novel linkers. These efforts are designed to enhance precision, stability, and efficacy in ADC programs.

With an inventory of over 1000 linker products, we support researchers with a broad array of high-quality options. Furthermore, our comprehensive customization services cater to diverse research objectives, enabling tailored solutions that align with the specific needs of each ADC project.